Genexine Financials
| 095700 Stock | KRW 5,930 30.00 0.51% |
Genexine |
Understanding current and past Genexine Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genexine's financial statements are interrelated, with each one affecting the others. For example, an increase in Genexine's assets may result in an increase in income on the income statement.
Please note, the presentation of Genexine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genexine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genexine's management manipulating its earnings.
Genexine Stock Summary
Genexine competes with ABL Bio, and Medy Tox. Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.| Instrument | Korea Stock View All |
| Exchange | KOSDAQ |
| ISIN | KR7095700001 |
| Business Address | Korea Bio Park |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.genexine.com |
| Phone | 82 3 1628 3200 |
| Currency | KRW - South Korean Won |
You should never invest in Genexine without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Genexine Stock, because this is throwing your money away. Analyzing the key information contained in Genexine's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Genexine Key Financial Ratios
Genexine's financial ratios allow both analysts and investors to convert raw data from Genexine's financial statements into concise, actionable information that can be used to evaluate the performance of Genexine over time and compare it to other companies across industries.| Return On Equity | -10.06 | |||
| Return On Asset | -0.0172 | |||
| Target Price | 121750.0 | |||
| Number Of Employees | 123 | |||
| Beta | 0.88 |
Genexine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genexine's current stock value. Our valuation model uses many indicators to compare Genexine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genexine competition to find correlations between indicators driving Genexine's intrinsic value. More Info.Genexine is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Genexine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Genexine's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Genexine Systematic Risk
Genexine's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genexine volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Genexine correlated with the market. If Beta is less than 0 Genexine generally moves in the opposite direction as compared to the market. If Genexine Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genexine is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genexine is generally in the same direction as the market. If Beta > 1 Genexine moves generally in the same direction as, but more than the movement of the benchmark.
Genexine December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Genexine help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genexine. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genexine based on widely used predictive technical indicators. In general, we focus on analyzing Genexine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genexine's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 36.92 | |||
| Value At Risk | (4.38) | |||
| Potential Upside | 2.96 |
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |